Completed
A Study of LY3127804 with Ramucirumab in Participants with Advanced Solid Tumors
I7W-MC-JQBA - ClinicalTrials.gov - NCT02597036
The main purpose of this study is to evaluate the safety of the study drug known as LY3127804 given as monotherapy and in combination with Ramucirumab for participants with advanced or metastatic solid tumors. The study will also include a safety exploration for the combination of LY3127804 plus ramucirumab and paclitaxel.
How long will I be in the trial?
Your participation could last up to 2 months depending on how you and your tumor respond.
Completed
A Study of LY3127804 with Ramucirumab in Participants with Advanced Solid Tumors
I7W-MC-JQBA - ClinicalTrials.gov - NCT02597036
The main purpose of this study is to evaluate the safety of the study drug known as LY3127804 given as monotherapy and in combination with Ramucirumab for participants with advanced or metastatic solid tumors. The study will also include a safety exploration for the combination of LY3127804 plus ramucirumab and paclitaxel.
How long will I be in the trial?
Your participation could last up to 2 months depending on how you and your tumor respond.
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have a diagnosis of cancer that is advanced and/or metastatic
Participant must have adequate organ function
Participants must NOT
Participant must not have any current blood cancers
Participant must not have an active fungal, bacterial, and/or known viral infection
Participant must not have a history or dangerously high blood pressure, headache, convulsions, or coma related to high blood pressure or poorly controlled hypertension despite standard medical management
Participant must not be pregnant or breastfeeding
Trial Summary
Conditions the trial is for
Solid Tumor
What the trial is testing?
LY3127804, Ramucirumab, Paclitaxel
Could I receive a Placebo?
no
Enrollment Goal
105
Trial Dates
November 2015 - May 2020
Trial Phase
1
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have a diagnosis of cancer that is advanced and/or metastatic
Participant must have adequate organ function
Participants must NOT
Participant must not have any current blood cancers
Participant must not have an active fungal, bacterial, and/or known viral infection
Participant must not have a history or dangerously high blood pressure, headache, convulsions, or coma related to high blood pressure or poorly controlled hypertension despite standard medical management
Participant must not be pregnant or breastfeeding
Trial Summary
Conditions the trial is for
Solid Tumor
What the trial is testing?
LY3127804, Ramucirumab, Paclitaxel
Could I receive a Placebo?
no
Enrollment Goal
105
Trial Dates
November 2015 - May 2020
Trial Phase
1
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Solid Tumor Resources
